Navigation Links
National Coalition for Quality Colorectal Cancer Screening and Care Testifies Before FDA Advisory Panel on Fospropofol Labeling:
Date:5/16/2008

Coalition Board Member Educates FDA on Concerns that Improper Labeling of

Fospropofol Will Negatively Impact Patient Safety during Colonoscopy

Screenings

ANNAPOLIS, Md., May 16 /PRNewswire/ -- Dr. Stanford Plavin, Board Vice Chairperson of the National Coalition for Quality Colorectal Cancer Screening and Care ("Coalition"), a 501(c) 6 not-for-profit association, testified on May 7th before the U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee relating to the importance of patient safety when anesthetic agents are administered during colonoscopy screenings.

"I am extremely pleased that the FDA Advisory Committee chose to consider patient access and safety first and foremost in their analysis of fospropofol and how it should be administered," said Dr. Plavin, managing partner of Ambulatory Anesthesia of Atlanta, P.C. "While the recommendations of the FDA Advisory Committee are not binding, it speaks for itself that the Committee members voted nine to one to restrict the use of fospropofol. This agent should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the surgical/diagnostic procedure. The practitioner administering fospropofol for sedation/anesthesia should have the education and training to identify and manage the airway and cardiovascular changes which occur in a patient who enters a state of general anesthesia, as well as the ability to assist in the management of complications."

"A primary goal of the Coalition is to promote safe sedation for colorectal cancer screening," notes Steven J. Morris, MD JD FACP FACG, Coalition Board Chairperson and CEO of Atlanta Gastroenterology Associates, LLC. "The Coalition is dedicated to ensure that patient care and quality is never compromised. Minimizing appropriate clinical oversight in an attempt to save dollars, at the expense of patient safety or at the cost of human lives, is unacceptable."

The Coalition, comprised of gastroenterologists, surgeons, primary care physicians, oncologists, anesthesiologists, patient advocacy groups, and concerned individuals, supports a sustained effort of advocacy, collaboration, research, and education geared toward key stakeholders, including the public.

Dr. Morris notes, "Access to optimal agents for sedation delivered by appropriately trained professionals is critical in order to encourage patients to undergo screening colonoscopies. We applaud the recommendations of the FDA Advisory Committee and look forward to their formal adoption by the FDA."

To learn more about the activities of the Coalition, visit http://www.preventingcolorectalcancer.org. You can contact the Coalition at (866) 461-9296 (toll free) or via email to info@preventingcolorectalcancer.org.

Headquartered in Annapolis, Maryland, the National Coalition for Quality Colorectal Cancer Screening & Care (http://www.preventingcolorectalcancer.org) has been established to preserve the tradition of safe, comfortable and quality-based medicine. The mission of the Coalition is to educate the public and key stakeholders about the opportunities to reduce the incidence of colorectal cancer through maintaining screening and care options for patients.


'/>"/>
SOURCE National Coalition for Quality Colorectal Cancer Screening& Care
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Research talent wins national Innovation in Nursing award
2. China Yingxia International, Inc. Reports First Quarter 2008 Results
3. National Quality Forum Endorses Consensus Standards for Quality of Hospital Care
4. Animal behavior turned into robots and more at 4th international AMAM symposium
5. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
6. Physical Therapists Offer Tips for Proper Bike Fit in Support of National Bike to Work Day
7. International Diabetes Federation gives grant to diabetes screening & prevention program in Vietnam
8. Service Corporation International Declares Quarterly Cash Dividend
9. National Business Group on Health Awards Gold to Blue Cross and Blue Shield of Minnesota for Promoting a Healthy Workplace
10. International Diabetes Federation gives grant to metabolic syndrome research project in Australia
11. Stop Obesity Alliance, Chair Dr. Richard H. Carmona, National Opinion Research Center Reveal Findings of Survey Showing Employer Concern About Health, Financial Costs of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name ... New York, NY, on December 3rd, to benefit Holy Name Medical Center's programs ... event, which raised over $1 million - the largest event in the Center's ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Cable Network (PCN) during the summer of 2016. The program was made possible ... the United States Department of Health and Human Services Administration. The broadcast, ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying record-breaking attendance at ... for its 33rd Annual Issues & Research Conference, March 2-3, 2017, at ... the conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest Healthcare Properties ... by an affiliate of Seavest, has won a prestigious national healthcare real estate ... ambulatory care center (ACC) was named “Best New Development, MOBs and Other Outpatient ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, ... Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related to ... prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 with ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Dec 9, 2016 Research and Markets has ... report to their offering. ... The global travel vaccines market to grow at ... report covers the present scenario and the growth prospects of the ... the report considers the revenue generated from the sales of various ...
(Date:12/9/2016)... , Dec. 9, 2016  Axovant Sciences ... clinical-stage biopharmaceutical company focused on the treatment of ... data from a Phase 2b trial evaluating treatment ... donepezil, compared with donepezil plus placebo in people ... the addition of intepirdine to treatment was associated ...
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... offer newly issued shares of common stock, $0.01 par value ... an underwritten public offering.  The final terms of the Offering ... of pricing, and there can be no assurance as to ... IRIDEX expects to use the net proceeds it will receive ...
Breaking Medicine Technology: